Home > Pulmonology > ERS 2019 > COPD Management > COPD Patients Derive Clinical Benefit from β-blockers

COPD Patients Derive Clinical Benefit from β-blockers

Presented By
Dr Anne Nielsen, Zealand University Hospital, Denmark
ERS 2019

A large observational study from Denmark showed that chronic obstructive pulmonary disease (COPD) patients treated with β-blockers did not only have fewer hospitalisations but also a lower total mortality compared with COPD patients treated with other antihypertensive drugs [1].

The study presented by Dr Anne Nielsen (Zealand University Hospital, Denmark) compared 301,542 COPD patients who were new users of β-blockers with more than a million new users of any other antihypertensive drugs [2]. The participants were aged 30-90 years and had no history of COPD hospitalisations. From 1995-2015, participants were followed in the Danish National Patient Registry for hospital admissions for COPD, all-cause mortality, and COPD associated death.

Overall, people treated continuously with β-blockers for more than 6 months had a 20% lower relative risk for COPD hospitalisation in the follow-up period compared with patients treated with other antihypertensives. ...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on